论文部分内容阅读
目的观察健择(GEM)联合顺铂(DDP)治疗晚期非小细胞肺癌(non-sm all cell lungcancer,NSCLC)的疗效和毒性反应。方法50例晚期非小细胞肺癌患者应用GP联合方案化疗,健择1 000 mg/m2,静滴30 m in,第1,8天;顺铂25 mg/m2,静滴1 h,第1~3天,每21 d为1周期,至少2周期。结果全组完全缓解(CR)1例,部分缓解(PR)21例,总有效率为44.0%。中位生存期为11个月,1年生存率为40.0%。Ⅲ度和Ⅳ度白细胞减少症和血小板减少症发生率分别为18.0%和16.0%。结论健择联合顺铂治疗晚期NSCLC有较好的疗效,且安全耐受性较好。
Objective To observe the efficacy and toxicity of gemcitabine combined with cisplatin (DDP) in the treatment of advanced non-sm all cell lung cancer (NSCLC). Methods 50 cases of advanced non-small cell lung cancer patients with GP combined chemotherapy, Gemcitabine 1 000 mg / m2, intravenous infusion of 30 m in, first and eighth days; cisplatin 25 mg / m2, intravenous infusion 1 h, 3 days, 1 cycle every 21 days, at least 2 cycles. Results The complete remission (CR) in 1 case, partial response (PR) in 21 cases, the total effective rate was 44.0%. The median survival was 11 months and the 1-year survival rate was 40.0%. Grade III and IV leucopenia and thrombocytopenia were 18.0% and 16.0%, respectively. Conclusion Gemcitabine combined with cisplatin in the treatment of advanced NSCLC has better curative effect and better safety tolerance.